ACE2 and COVID-19: Recently, Tian et al. [50] used ELISA and Biolayer Interferometry Binding to demonstrate that one SARS-CoV-specific antibody, CR3022, binds with COVID-19 RBD and, more crucially, that this antibody does not compete with ACE-2 for binding to COVID-19 RBD.